ABOUT US

History

현재's

  • 02

    Supply of patent avoidance Safinamide

2024's

  • 12

    Exclusive supply of crystalline patent avoidance Apalutamide

  • 09

    Salt Change Ruxolitinib Hemifumariate Exclusive Supply

  • 01

    IVY DMF site-audit

2023's

  • 12

    Commendation from the Mayor of Seongnam for Sponsor Appreciation Day

  • 11

    Supply of patent avoidance Lenvatinib

  • 04

    Joint host of Dr. Reddy's K-science conference

  • 02

    Supply of Pancreatine pellet

2022's

  • 07

    Supply of patent avoidance Aripiprazole

  • 03

    Supply of Tofacitinib Citrate XR Semi-product

  • 02

    KDMF for Almagate approved

2021's

  • 02

    Empagliflozin1st generic development

  • 20th anniverary

2020's

  • 07

    KDMF for Empagliflozin amorphous(new crystalline) approved

  • 05

    KDMF for Sugammadex sodium approved

2019's

  • 04

    KDMF for Dapagliflozin(new salt) approved

  • Apixaban 1st generic development

2018's

  • 02

    KDMF for Mirabegron approved

2017's

  • 12

    KDMF for Sitagliptin HCl(new salt) approved

2016's

  • 12

    Over 40 million USD of annual turnover